To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.

Exclusion Criteria

• •1. Who have not been diagnosed with malignant blood diseases (acute myelogenous leukemia, acute lymphocytic leukemia, non-Hodgkins lymphoma, Hodgkins lymphoma, multiple myelopathy) within 5 years of screening criteria
• •2. Patients with severe aplastic anemia
• •3. Patients with solid cancers in their previous medical history (within 5 years)
• •4. Patients whose blood serum AST/ASL rates are more than three times the normal maximum rate, and whose creatinine rates are more than 1.5 times the normal maximum rate (but AST in myocardial infarction patients can temporarily rise, thus, as decided by the researchers, if there is no damage to the liver function, the rise will not be taken into consideration)
• •5. Patients who have implemented Coronary Artery Bypass Graft(CABG)
• •6. Patients with chronic heart failure (patients with medical history of heart failure medical history at least three months before the occurrence of acute myocardial infarction)
• •7. Patients who cannot proceed with cardiac catheterization
• •8. Patients who had been continuously taking large doses of steroids (1mg/kg/day) or antibiotics for severe infections from one month prior to registration
• •9. Patients who had major surgical operations, organ biopsy, or significant external injury as determined by the researcher, within three months before registration
• •10. Patients who have head injuries or other external injuries after the development of myocardial infarction
• •11. patients with stroke or transient ischemic attack within six months before registration, patients with history of central nervous system disease (tumor, aneurysm, brain surgery etc.)
• •12. Patients with low survival ability after cardiopulmonary resuscitation within last 2 weeks.
• •13. Patients with positive for HIV, HBV, HCV, Syphilis
• •14. pregnant women or likely to be pregnant or lactating women
• •15. Patients with drug abuser within last 1 year.
• •16. Patients with participating other clinical trials with last 1 month.
• •17. When the possibility of tumor occurrence is seen when the tester judges even one of the tumor marker tests during screening
• •18. Who are judged to be inappropriate to participate in this test when judged by the examiner